The biotech sector is a study in contrasts, where a single regulatory decision can spell disaster for one firm while another methodically advances its pipeline.

Silver prices are being propelled by a potent combination of immediate geopolitical anxiety and a deepening structural ...

The stark divide between ServiceNow's operational performance and its stock price has never been wider. While the company ...

A dramatic shift in capital flows is reshaping the Bitcoin market, providing a powerful counterweight to persistent ...

OMV navigates oil market volatility, a major portfolio transformation, and a key investor reducing its stake, with Q1 2026 ...

ABO Energy's stock shows a technical signal after an 85% plunge. While facing a massive 2025 loss, its renewable project ...

Xiaomi's stock hits lows despite AI model success and strong EV orders, as tariffs, rising costs, and a profit squeeze ...

Amazon shares closed the week on a strong note, buoyed by a strategic pharmaceutical partnership and sustained momentum in its cloud division. The stock gained ...

A dramatic fee cut by a major competitor has intensified pressure on the iShares Core MSCI World UCITS ETF, the world's largest equity ETF with roughly €110.9 b ...

Commerzbank shares are riding a wave of bullish momentum, but a hidden regulatory trap in Poland could sink a multi-billion euro takeover attempt. As the German ...

While the broader crypto market grapples with extreme fear, a distinct and more constructive narrative is quietly building ...

UBS AGM to decide on 22% dividend hike and new board members as Swiss regulators consider new rules that could impose $26B in extra capital requirements on the bank.